Chengdu, Sichuan, China · Est. 2002
Sichuan Kelun-Biotech is a Chinese biopharmaceutical company specializing in the research, development, and manufacturing of biologics and innovative drugs.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
6 drugs in development
By Therapeutic Area
top 1
R&D Momentum
74/100
Pipeline Velocity
47/100
Trial Completion Rate
100/100
Pipeline Concentration
76/100
Pipeline Freshness
84/100
Activity
Last 14 days
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB118 Injection in Participants With Advanced Solid Tumors
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)